Literature DB >> 27801556

Progress towards eliminating onchocerciasis in the WHO Region of the Americas: verification of elimination of transmission in Guatemala.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27801556

Source DB:  PubMed          Journal:  Wkly Epidemiol Rec        ISSN： 0049-8114


× No keyword cloud information.
  18 in total

1.  Evaluation of an OV-16 IgG4 Enzyme-Linked Immunosorbent Assay in Humans and Its Application to Determine the Dynamics of Antibody Responses in a Non-Human Primate Model of Onchocerca volvulus Infection.

Authors:  Vitaliano A Cama; Circe McDonald; Alice Arcury-Quandt; Mark Eberhard; M Harley Jenks; Jared Smith; Sindew M Feleke; Francisca Abanyie; Lakwo Thomson; Ryan E Wiegand; Paul T Cantey
Journal:  Am J Trop Med Hyg       Date:  2018-10       Impact factor: 2.345

2.  The interruption of transmission of onchocerciasis in Kaduna, Kebbi and Zamfara states, Nigeria: another milestone achievement.

Authors:  Sunday Isiyaku; Michael Igbe; Suzie Madaki; Louise C Hamill; Patrick Ndongmo; William Adamani; Simon Bush; Joy Shu'aibu; Elizabeth Elhassan; Yisa Saka; Chukwuma Anyaike; Nse Michael Akpan; Akilah Joel; Audrey Nyior; Alhassan Abdullahi; Attahiru Aleiro; Abdullahi Labbo; Hayward Babale Mafuyai; Bertram E B Nwoke
Journal:  Int Health       Date:  2022-09-21       Impact factor: 3.131

3.  Integrating Multiple Biomarkers to Increase Sensitivity for the Detection of Onchocerca volvulus Infection.

Authors:  Sasisekhar Bennuru; Georgiette Oduro-Boateng; Chinweoke Osigwe; Priscilla Del Valle; Allison Golden; Guilherme Maerschner Ogawa; Vitaliano Cama; Sara Lustigman; Thomas B Nutman
Journal:  J Infect Dis       Date:  2020-05-11       Impact factor: 7.759

4.  River-specific macrogenomic diversity in Simulium guianense s. l. (Diptera: Simuliidae), a complex of tropical American vectors associated with human onchocerciasis.

Authors:  Peter H Adler; Neusa Hamada; Jeane Marcelle Cavalcante do Nascimento; Maria Eugenia Grillet
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

5.  Important progress towards elimination of onchocerciasis in the West Region of Cameroon.

Authors:  Guy-Roger Kamga; Fanny N Dissak-Delon; Hugues C Nana-Djeunga; Benjamin D Biholong; Stephen Mbigha Ghogomu; Jacob Souopgui; Joseph Kamgno; Annie Robert
Journal:  Parasit Vectors       Date:  2017-08-03       Impact factor: 3.876

6.  Onchocerca volvulus infection and serological prevalence, ocular onchocerciasis and parasite transmission in northern and central Togo after decades of Simulium damnosum s.l. vector control and mass drug administration of ivermectin.

Authors:  Kossi Komlan; Patrick S Vossberg; Richard G Gantin; Tchalim Solim; Francois Korbmacher; Méba Banla; Koffi Padjoudoum; Potchoziou Karabou; Carsten Köhler; Peter T Soboslay
Journal:  PLoS Negl Trop Dis       Date:  2018-03-01

7.  Onchocerca volvulus infection in Tihama region - west of Yemen: Continuing transmission in ivermectin-targeted endemic foci and unveiled endemicity in districts with previously unknown status.

Authors:  Mohammed A K Mahdy; Rashad Abdul-Ghani; Thaker A A Abdulrahman; Samira M A Al-Eryani; Abdulsalam M Al-Mekhlafi; Sami A A Alhaidari; Ahmed A Azazy
Journal:  PLoS Negl Trop Dis       Date:  2018-03-05

8.  Transitioning from river blindness control to elimination: steps toward stopping treatment.

Authors:  Paul T Cantey; Sharon L Roy; Daniel Boakye; Upendo Mwingira; Eric A Ottesen; Adrian D Hopkins; Yao K Sodahlon
Journal:  Int Health       Date:  2018-03-01       Impact factor: 3.131

9.  Upon entering an age of global ivermectin-based integrated mass drug administration for neglected tropical diseases and malaria.

Authors:  Frank O Richards
Journal:  Malar J       Date:  2017-04-24       Impact factor: 2.979

10.  From river blindness control to elimination: bridge over troubled water.

Authors:  Robert Colebunders; Maria-Gloria Basáñez; Katja Siling; Rory J Post; Anke Rotsaert; Bruno Mmbando; Patrick Suykerbuyk; Adrian Hopkins
Journal:  Infect Dis Poverty       Date:  2018-03-28       Impact factor: 4.520
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.